Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Merck drug wins FDA nod as first-line lung cancer treatment
Pharmalot By Ed Silverman Interfaith investor coalition pushes shareholder resolutions on drug prices
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Alkermes depression drug now looks promising, but will FDA bite?
Business By Rebecca Robbins The insulin market is heading for a shakeup. But patients may not benefit
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: FDA staff questions effectiveness of Merck antibiotic
Pharmalot By Ed Silverman Gilead won’t have to pay $200 million in patent case because Merck lawyer lied
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Investors tell pharma to ‘take control’ of the pricing debate
The Pharmalot View By Ed Silverman Big drug maker presses for money-back guarantee that its science will work
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: China probing drug and device makers for antitrust violations
Pharmalot By Ed Silverman Switching to newest HPV vaccine can save billions in health care costs, study says
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Gilead ordered to pay $200m to Merck in patent row